Tissue Plasminogen Activator Market – Global Growth Forecast Up To 2026

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.

tPA is also be produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2469

Global Tissue Plasminogen Activator Market: Drivers

Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidences of stroke has boosted the tissue plasminogen activator market size. According to John Hopkins Medicines (JHM) in the U.S., around 795,000 people in the U.S. suffer from stroke per year, as reported in 2014. According to the World Health Organization (WHO), stroke is the second leading cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major factors driving the tissue plasminogen activator market growth.

Global Tissue Plasminogen Activator Market: Regional Analysis

North America is the leader in the global tissue plasminogen activator market, owing to rising awareness about stroke and huge spending on treatment of stroke. For instance, in 2017, the American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every year, which includes medicines for the treatment of stroke and cost of health care services.

Asia pacific is the fastest growing region in the tissue plasminogen activator market, owing to increasing demand drug coupled with rising stroke incidences in the region. According to WHO, Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.

Global Tissue Plasminogen Activator Market: Competitive Landscape

Key players operating in the global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.

Global Tissue Plasminogen Activator Market: Taxonomy

The global tissue plasminogen activator market is segmented on the basis of dosage, route of administration, application, and region.

By Route of administration:

• Intravenous
• Regional intra-arterial

By Application:

• Blood clots
• Pulmonary embolism
• Myocardial infarction
• Stroke

For More Information, Browse Complete Report Here: https://www.coherentmarketinsights.com/ongoing-insight/tissue-plasminogen-activator-market-2469

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com